This is a phase II precision medicine cancer trial with nearly 40 treatment arms. See study details. Patients with advanced solid tumors, lymphomas, or myeloma may be eligible, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment. Some arms have exceptions. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6,000 patients tested in this trial.

Total accrual: 2000 as of 12/23/2022

http://ecog-acrin.org/trials/nci-match-eay131

For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Emailcancer@cchmc.org